Key result
Intrinsic antitachycardia pacing successfully terminates multiple distinct VTs without conventional ATP or shocks.
Why the study?
Antitachycardia pacing (ATP) has limitations including low success rates for fast VT and risk of VT acceleration, and the effectiveness of intrinsic ATP (iATP) against multiple VTs in the same patient was not previously demonstrated.
Case Report (n=2)
Answers are grounded in this paper and cite their sources.
Case series reveals successful termination of multiple ventricular tachycardias by intrinsic antitachycardia pacing in ICD recipients, highlighting the efficacy of individualized automated pacing.
Antitachycardia pacing (ATP) offers a safe and painless termination of ventricular tachycardia (VT) in patients with implantable cardioverter-defibrillators (ICDs).1 However, it is accompanied with some limitations: ATP success rates are as low as 50% for fast VT, with a cycle length (CL) of <300 ms, and VT acceleration may occur in up to 10% of ATP therapies.2,3 Intrinsic antitachycardia pacing (iATP) provides an automatic and tailored ATP for each VT in real time.4 An iATP algorithm delivers the equivalent of a train of burst pulses (S1) followed by 1 (S2) or 2 (S2-S3) ramp-plus pulses.
No takes yet. Share an insight, caveat, or question.
Okubo et al. (2022) conducted a case report in Ventricular tachycardia in dilated cardiomyopathy (n=2). Intrinsic antitachycardia pacing (iATP) was evaluated on Termination of ventricular tachycardia. Intrinsic antitachycardia pacing successfully terminated multiple distinct ventricular tachycardias in two patients with dilated cardiomyopathy without the need for conventional ATP or shocks.
Synapse has enriched 10 related papers. Consider them for comparative context: